Eric Butz

Oct 16, 2024 | manilatimes.net | Ed Calamai |Stanley Roberts |Eric Butz

PHILADELPHIA, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context” or "Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, today announced a poster regarding the Company's clinical asset, CTIM-76, a Claudin 6 x CD3 bispecific antibody will be presented at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting, being held November 8-10, 2024 at the George R. Brown Convention Center in Houston, TX.

Oct 16, 2024 | stocktitan.net | Ed Calamai |Stanley Roberts |Eric Butz |Kelly Byrnes-Blake

Rhea-AI Impact Rhea-AI Sentiment Context Therapeutics Inc. (Nasdaq: CNTX), a biopharmaceutical company focused on T cell engagers for solid tumors, has announced a poster presentation at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting. The presentation will feature their clinical asset CTIM-76, a Claudin 6 x CD3 bispecific antibody.